| abstract |
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof. |